Publications

論文(英文)

  1. Naganuma F, Nakamura T, Kuroyanagi H, Tanaka M, Yoshikawa T, Yanai K, Okamura N. Chemogenetic modulation of histaminergic neurons in the tuberomamillary nucleus alters territorial aggression and wakefulness. Sci Rep. 2021; 11: 17935.
  2. Filip T, Mairinger S, Neddens J, Sauberer M, Flunkert S, Stanek J, Wanek T, Okamura N, Langer O, Hutter-Paier B, Kuntner C. Characterization of an APP/tau rat model of Alzheimer’s disease by positron emission tomography and immunofluorescent labeling. Alzheimers Res Ther. 2021; 13: 175.
  3. Uchida Y, Horimoto Y, Shibata H, Kuno T, Usami T, Takada K, Iida A, Ueki Y, Okamura N, Matsukawa N. Occipital tau deposition and astrogliosis after traumatic brain injuries in a kendo player. Neurol Clin Pract. 2021; 11: e579-e581.
  4. Alzghool OM, Rokka J, López-Picón FR, Snellman A, Helin JS, Okamura N, Solin O, Rinne JO, Haaparanta-Solin M. (S)-[18F]THK5117 brain uptake is associated with Aβ plaques and MAO-B enzyme in a mouse model of Alzheimer’s disease. Neuropharmacology. 2021; 196: 108676.
  5. Naganuma F, Yoshikawa T. Organic cation transporters in brain histamine clearance: Physiological and psychiatric implications. Handb Exp Pharmacol. 2021 DOI: 10.1007/164_2021_447
  6. Lee HJ, Lee EC, Seo S, Ko KP, Kang JM, Kim WR, Seo HE, Lee SY, Lee YB, Park KH, Yeon BK, Okamura N, Na DL, Seong JK, Noh Y. Identification of heterogeneous subtypes of mild cognitive impairment using cluster analyses based on PET imaging of tau and astrogliosis. Front Aging Neurosci. 2021; 12: 615467.
  7. Morito T, Harada R, Iwata R, Du Y, Okamura N, Kudo Y, Yanai K. Synthesis and pharmacokinetic characterisation of a fluorine-18 labelled brain shuttle peptide fusion dimeric affibody. Sci Rep. 2021; 11: 2588.
  8. Yosikawa T, Nakamura T, Yanai K. Histaminergic neurons in the tuberomammillary nucleus as a control centre for wakefulness. Br J Pharmacol. 2021; 178: 750-769.
  9. Harada R, Hayakawa Y, Ezura M, Lerdsirisuk P, Du Y, Ishikawa Y, Iwata R, Shidahara M, Ishiki A, Kikuchi A, Arai H, Kudo Y, Yanai K, Furumoto S, Okamura N. 18 F-SMBT-1: A selective and reversible positron-emission tomography tracer for monoamine oxidase-B imaging. J Nucl Med. 2021; 62: 253-258.
  10. Lerdsirisuk P, Harada R, Hayakawa Y, Shimizu Y, Ishikawa Y, Iwata R, Kudo Y, Okamura N, Furumoto S. Synthesis and evaluation of 2-pyrrolopyridinylquinoline derivatives as selective tau PET tracers for the diagnosis of Alzheimer’s disease. Nucl Med Biol. 2020; 93: 11-18.
  11. Hsu JL, Chen SH, Hsiao IT, Lu CS, Yen TC, Okamura N, Lin KJ, Weng YH. 18F-THK5351 PET imaging in patients with progressive supranuclear palsy: associations with core domains and diagnostic certainty. Sci Rep. 2020; 10: 19410.
  12. Huang KL, Hsiao IT, Ho MY, Hsu JL, Chang YJ, Chang TY, Liu CH, Chang CH, Wu YM, Wu KY, Wey SP, Yen TC, Okamura N, Lee TH, Lin KJ. Investigation of reactive astrogliosis effect on post-stroke cognitive impairment. J Neuroinflammation. 2020; 17: 308.
  13. Bandaru SS, Khanday MA, Ibrahim N, Naganuma F, Vetrivelan R. Sleep-Wake Control by Melanin-Concentrating Hormone (MCH) Neurons: a Review of Recent Findings. Curr Neurol Neurosci Rep. 2020; 20: 55.
  14. Yamada Y, Yoshikawa T, Naganuma F, Kikkawa T, Osumi N, Yanai K. Chronic brain histamine depletion in adult mice induced depression-like behaviours and impaired sleep-wake cycle. Neuropharmacology 2020; 175: 108179.
  15. Jeong HJ, Lee H, Lee SY, Seo S, Park KH, Lee YB, Shin DJ, Kang JM, Yeon BK, Kang SG, Cho J, Seong JK, Okamura N, Villemagne VL, Na DL, Noh Y. [¹⁸F]THK5351 PET Imaging in Patients with Mild Cognitive Impairment. J Clin Neurol. 2020; 16: 202-214.
  16. Mairinger S, Filip T, Sauberer M, Flunkert S, Wanek T, Stanek J, Furtner S, Hutter-Paier B, Okamura N, Kuntner C. Plasma pharmacokinetic and metabolism of [18F]THK-5317 are dependent on sex. Nucl Med Biol. 2020; 84-85: 28-32.
  17. Gersel Stokholm M, Iranzo A, Østergaard K, Serradell M, Otto M, Bacher Svendsen K, Garrido A, Vilas D, Fedorova TD, Santamaria J, Møller A, Gaig C, Hiraoka K, Brooks DJ, Okamura N, Borghammer P, Tolosa E, Pavese N. Cholinergic denervation in patients with idiopathic rapid eye movement sleep behaviour disorder. Eur J Neurol. 2020; 27: 644-652.
  18. Kárpáti A, Yoshikawa T, Naganuma F, Matsuzawa T, Kitano H, Yamada Y, Yokoyama M, Futatsugi A, Mikoshiba K, Yanai K. Histamine H1 receptor on astrocytes and neurons controls distinct aspects of mouse behaviour. Sci Rep. 2019; 9: 16451.
  19. Schönecker S, Brendel M, Palleis C, Beyer L, Höglinger GU, Schuh E, Rauchmann BS, Sauerbeck J, Rohrer G, Sonnenfeld S, Furukawa K, Ishiki A, Okamura N, Bartenstein P, Dieterich M, Bötzel K, Danek A, Rominger A, Levin J. PET imaging of astrogliosis and tau facilitates diagnosis of Parkinsonian syndromes. Front Aging Neurosci. 2019; 11: 249.
  20. Jeon S, Kang JM, Seo S, Jeong HJ, Funck T, Lee SY, Park KH, Lee YB, Yeon BK, Ido T, Okamura N, Evans AC, Na DL, Noh Y. Topographical heterogeneity of Alzheimer’s disease based on MR imaging, tau PET, and amyloid PET. Front Aging Neurosci. 2019; 11: 211.
  21. Nakamura T, Hiraoka K, Harada R, Matsuzawa T, Ishikawa Y, Funaki Y, Yoshikawa T, Tashiro M, Yanai K, Okamura N. Brain histamine H1 receptor occupancy after oral administration of desloratadine and loratadine. Pharmacol Res Perspect. 2019; 7: e00499.
  22. Saito K, Kaiho Y, Tamii T, Nakamura T, Kameyama E, Yamauchi M. Intraoperative hemorrhage in revision total hip arthroplasty: a retrospective single-center study. J Anesth. 2019; 33: 399-407.
  23. Kobayashi R, Hayashi H, Kawakatsu S, Okamura N, Yoshioka M, Otani K. Assessment of amyloid deposition in patients with probable REM sleep behavior disorder as a prodromal symptom of dementia with Lewy bodies using PiB-PET. Front Neurol. 2019; 10: 671.
  24. Ezura M, Kikuchi A, Ishiki A, Okamura N, Hasegawa T, Harada R, Watanuki S, Funaki Y, Hiraoka K, Baba T, Sugeno N, Oshima R, Yoshida S, Kobayashi J, Kobayashi M, Tano O, Nakashima I, Mugikura S, Iwata R, Taki Y, Furukawa K, Arai H, Furumoto S, Tashiro M, Yanai K, Kudo Y, Takeda A, Aoki M. Longitudinal changes in 18 F-THK5351 positron emission tomography in corticobasal syndrome. Eur J Neurol. 2019; 26: 1205-1211.
  25. Yoshikawa T, Nakamura T, Yanai K. Histamine N-Methyltransferase in the Brain. Int J Mol Sci. 2019; 20: 737.
  26. Naganuma F, Kroeger D, Bandaru SS, Absi G, Madara JC, Vetrivelan R. Lateral hypothalamic neurotensin neurons promote arousal and hyperthermia. PLoS Biol. 2019; 17: e3000172. 
  27. Naganuma F, Bandaru SS, Absi G, Chee MJ, Vetrivelan R. Melanin-concentrating hormone neurons promote rapid eye movement sleep independent of glutamate release. Brain Struct Funct. 2019; 224: 99-110. 
  28. Kamei M, Otani Y, Hayashi H, Nakamura T, Yanai K, Furuta K, Tanaka S. Suppression of IFN-γ Production in Murine Splenocytes by Histamine Receptor Antagonists. Int J Mol Sci. 2018; 19: 4083.
  29. Naganuma F, Bandaru SS, Absi G, Mahoney CE, Scammell TE, Vetrivelan R. Melanin-concentrating hormone neurons contribute to dysregulation of rapid eye movement sleep in narcolepsy. Neurobiol Dis. 2018; 120: 12-20.
  30. Yoon CW, Jeong HJ, Seo S, Lee SY, Suh MK, Heo JH, Lee YB, Park KH, Okamura N, Lee KM, Noh Y. 18F-THK5351 PET Imaging in Nonfluent-Agrammatic Variant Primary Progressive Aphasia. Dement Neurocogn Disord. 2018; 17: 110-119.
  31. Tago T, Toyohara J, Harada R, Furumoto S, Okamura N, Kudo Y, Takahashi-Fujigasaki J, Murayama S, Ishii K. Characterization of the binding of tau imaging ligands to melanin-containing cells: putative off-target-binding site. Ann Nucl Med. 2019; 33: 375-382.
  32. Shigemoto Y, Sone D, Maikusa N, Okamura N, Furumoto S, Kudo Y, Ogawa M, Takano H, Yokoi Y, Sakata M, Tsukamoto T, Kato K, Sato N, Matsuda H. Association of deposition of tau and amyloid-β proteins with structural connectivity changes in cognitively normal older adults and Alzheimer’s disease spectrum patients. Brain Behav. 2018: e01145.
  33. Yokoi T, Watanabe H, Yamaguchi H, Bagarinao E, Masuda M, Imai K, Ogura A, Ohdake R, Kawabata K, Hara K, Riku Y, Ishigaki S, Katsuno M, Miyao S, Kato K, Naganawa S, Harada R, Okamura N, Yanai K, Yoshida M, Sobue G. Involvement of the precuneus/posterior cingulate cortex is significant for the development of Alzheimer’s disease: a PET (THK5351, PiB) and resting fMRI study. Front Aging Neurosci. 2018; 10: 304.
  34. Nai YH, Watanuki S, Tashiro M, Okamura N, Watabe H. Investigation of the quantitative accuracy of low-dose amyloid and tau PET imaging. Radiol Phys Technol. 2018; 11: 451-459.
  35. Harada R, Okamura N, Furumoto S, Yanai K. Imaging protein misfolding in the brain using β-Sheet ligands. Front Neurosci. 2018; 12: 585.
  36. Sedjahtera A, Gunawan L, Bray L, Hung LW, Parsons J, Okamura N, Villemagne VL, Yanai K, Liu XM, Chan J, Bush AI, Finkelstein DI, Barnham KJ, Cherny RA, Adlard PA. Targeting metals rescues the phenotype in an animal model of tauopathy. Metallomics. 2018; 10: 1339-1347.
  37. Okamura N, Harada R, Ishiki A, Kikuchi A, Nakamura T, Kudo Y. The development and validation of tau PET tracers: current status and future directions. Clin Transl Imaging. 2018; 6: 305-316.
  38. Kobayashi R, Hayashi H, Kawakatsu S, Ishiki A, Okamura N, Arai H, Otani K. [18F]THK-5351 PET imaging in early-stage semantic variant primary progressive aphasia: a report of two cases and a literature review. BMC Neurol. 2018; 18: 109.
  39. Shigemoto Y, Sone D, Imabayashi E, Maikusa N, Okamura N, Furumoto S, Kudo Y, Ogawa M, Takano H, Yokoi Y, Sakata M, Tsukamoto T, Kato K, Sato N, Matsuda H. Dissociation of tau deposits and brain atrophy in early Alzheimer’s disease: A combined positron emission tomography/magnetic resonance imaging study. Front Aging Neurosci. 2018; 10: 223.
  40. Huang KL, Hsu JL, Lin KJ, Chang CH, Wu YM, Chang TY, Chang YJ, Liu CH, Ho MY, Wey SP, Yen TC, Okamura N, Hsiao IT, Lee TH. Visualization of ischemic stroke-related changes on 18F-THK-5351 positron emission tomography. EJNMMI Res. 2018; 8: 62.
  41. Schöberl F, Levin J, Remi J, Goldschagg N, Eren O, Okamura N, Unterrainer M, Rominger A, Albert N, Brendel M. IgLON5: A case with predominant cerebellar tau deposits and leptomeningeal inflammation. Neurology. 2018; 91: 180-182.
  42. Ishiki A, Harada R, Kai H, Sato N, Totsune T, Tomita N, Watanuki S, Hiraoka K, Ishikawa Y, Funaki Y, Iwata R, Furumoto S, Tashiro M, Sasano H, Kitamoto T, Kudo Y, Yanai K, Furukawa K, Okamura N, Arai H. Neuroimaging-pathological correlations of [18F]THK5351 PET in progressive supranuclear palsy. Acta Neuropathol Commun. 2018; 6: 53.
  43. Brendel M, Yousefi BH, Blume T, Herz M, Focke C, Deussing M, Peters F, Lindner S, von Ungern-Sternberg B, Drzezga A, Bartenstein P, Haass C, Okamura N, Herms J, Yakushev I, Rominger A. Comparison of 18F-T807 and 18F-THK5117 PET in a Mouse Model of Tau Pathology. Front Aging Neurosci. 2018; 10: 174.
  44. Leinonen V, Rauramaa T, Johansson J, Bottelbergs A, Tesseur I, van der Ark P, Pemberton D, Koivisto AM, Jääskeläinen JE, Hiltunen M, Herukka SK, Blennow K, Zetterberg H, Jokinen P, Rokka J, Helin S, Haaparanta-Solin M, Solin O, Okamura N, Kolb HC, Rinne JO. S-[18F]THK-5117-PET and [11C]PIB-PET Imaging in Idiopathic Normal Pressure Hydrocephalus in Relation to Confirmed Amyloid-β Plaques and Tau in Brain Biopsies. J Alzheimers Dis. 2018; 64: 171-179.
  45. Chiotis K, Stenkrona P, Almkvist O, Stepanov V, Ferreira D, Arakawa R, Takano A, Westman E, Varrone A, Okamura N, Shimada H, Higuchi M, Halldin C, Nordberg A. Dual tracer tau PET imaging reveals different molecular targets for 11C-THK5351 and 11C-PBB3 in the Alzheimer brain. Eur J Nucl Med Mol Imaging. 2018; 45: 1605-1617.
  46. Chen J, Li Y, Pirraglia E, Okamura N, Rusinek H, de Leon MJ; Alzheimer’s Disease Neuroimaging Initiative. Quantitative evaluation of tau PET tracers 18F-THK5351 and 18F-AV-1451 in Alzheimer’s disease with standardized uptake value peak-alignment (SUVP) normalization. Eur J Nucl Med Mol Imaging. 2018; 45: 1596-1604.
  47. Shimizu S, Imabayashi E, Takenoshita N, Okamura N, Furumoto S, Kudo Y, Matsuda H, Hanyu H. Case of progressive supranuclear palsy detected by tau imaging with [18F]THK-5351 before the appearance of characteristic clinical features. Geriatr Gerontol Int. 2018; 18: 501-502.
  48. Brendel M, Schönecker S, Höglinger G, Lindner S, Havla J, Blautzik J, Sauerbeck J, Rohrer G, Zach C, Vettermann F, Lang AE, Golbe L, Nübling G, Bartenstein P, Furukawa K, Ishiki A, Bötzel K, Danek A, Okamura N, Levin J, Rominger A. [18F]-THK5351 PET correlates with topology and symptom severity in progressive supranuclear palsy. Front Aging Neurosci. 2018; 9: 440.
  49. Harada R, Ishiki A, Kai H, Sato N, Furukawa K, Furumoto S, Tago T, Tomita N, Watanuki S, Hiraoka K, Ishikawa Y, Funaki Y, Nakamura T, Yoshikawa T, Iwata R, Tashiro M, Sasano H, Kitamoto T, Yanai K, Arai H, Kudo Y, Okamura N. Correlations of 18F-THK5351 PET with post-mortem burden of tau and astrogliosis in Alzheimer’s disease. J Nucl Med. 2018; 59: 671-674.
  50. Lee H, Seo S, Lee SY, Jeong HJ, Woo SH, Lee KM, Lee YB, Park KH, Heo JH, Yoon CW, Kang JM, Cho J, Okamura N, Furumoto S, Yanai K, Na DL, Ido T, Villemagne VL, Noh Y. [18F]-THK5351 PET Imaging in patients with semantic variant primary progressive aphasia. Alzheimer Dis Assoc Disord. 2018; 32: 62-69.
  51. Brendel M, Wagner L, Levin J, Zach C, Lindner S, Bartenstein P, Okamura N, Rominger A. Perfusion-Phase [18F]THK5351 Tau-PET Imaging as a Surrogate Marker for Neurodegeneration. J Alzheimers Dis Rep. 2017; 1: 109-113.
  52. Lemoine L, Gillberg PG, Svedberg M, Stepanov V, Jia Z, Huang J, Nag S, Tian H, Ghetti B, Okamura N, Higuchi M, Halldin C, Nordberg A. Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains. Alzheimers Res Ther. 2017; 9: 96.
  53. Naganuma F, Nakamura T, Yoshikawa T, Iida T, Miura Y, Kárpáti A, Matsuzawa T, Yanai A, Mogi A, Mochizuki T, Okamura N, Yanai K. Histamine N-methyltransferase regulates aggression and the sleep-wake cycle. Sci Rep. 2017; 7: 15899.
  54. Yanai K, Yoshikawa T, Yanai A, Nakamura T, Iida T, Leurs R, Tashiro M. The clinical pharmacology of non-sedating antihistamines. Pharmacol Ther. 2017; 178: 148-156.
  55. Betthauser TJ, Ellison PA, Murali D, Lao PJ, Barnhart TE, Furumoto S, Okamura N, Johnson SC, Engle JW, Nickles RJ, Christian BT. Characterization of the radiosynthesis and purification of [18F]THK-5351, a PET ligand for neurofibrillary tau. Appl Radiat Isot. 2017; 130: 230-237.
  56. Kang JM, Lee SY, Seo S, Jeong HJ, Woo SH, Lee H, Lee YB, Yeon BK, Shin DH, Park KH, Kang H, Okamura N, Furumoto S, Yanai K, Villemagne VL, Seong JK, Na DL, Ido T, Cho J, Lee KM, Noh Y. Tau positron emission tomography using [18F]THK5351 and cerebral glucose hypometabolism in Alzheimer’s disease. Neurobiol Aging. 2017; 59: 210-219.
  57. Sone D, Imabayashi E, Maikusa N, Okamura N, Furumoto S, Kudo Y, Ogawa M, Takano H, Yokoi Y, Sakata M, Tsukamoto T, Kato K, Matsuda H. Regional tau deposition and subregion atrophy of medial temporal structures in early Alzheimer’s disease: A combined positron emission tomography/magnetic resonance imaging study. Alzheimers Dement (Amst). 2017; 9: 35-40.
  58. Iida T, Yoshikawa T, Kárpáti A, Matsuzawa T, Kitano H, Mogi A, Harada R, Naganuma F, Nakamura T, Yanai K. JNJ10181457, a histamine H3 receptor inverse agonist, regulates in vivo microglial functions and improves depression-like behaviours in mice. Biochem Biophys Res Commun. 2017; 488: 534-540.
  59. Shidahara M, Thomas BA, Okamura N, Ibaraki M, Matsubara K, Oyama S, Ishikawa Y, Watanuki S, Iwata R, Furumoto S, Tashiro M, Yanai K, Gonda K, Watabe H. A comparison of five partial volume correction methods for Tau and Amyloid PET imaging with [18F]THK5351 and [11C]PIB. Ann Nucl Med. 2017; 31: 563-569.
  60. Ng KP, Pascoal TA, Mathotaarachchi S, Therriault J, Kang MS, Shin M, Guiot MC, Guo Q, Harada R, Comley RA, Massarweh G, Soucy JP, Okamura N, Gauthier S, Rosa-Neto P. Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain. Alzheimers Res Ther. 2017; 9: 25.
  61. Hsiao IT, Lin KJ, Huang KL, Huang CC, Chen HS, Wey SP, Yen TC, Okamura N, Hsu JL. Biodistribution and radiation dosimetry for the tau tracer 18F-THK-5351 in healthy human subjects. J Nucl Med. 2017; 58:1498-1503.
  62. de Leon MJ, Li Y, Okamura N, Tsui WH, Saint Louis LA, Glodzik L, Osorio RS, Fortea J, Butler T, Pirraglia E, Fossati S, Kim HJ, Carare RO, Nedergaard M, Benveniste H, Rusinek H. CSF clearance in Alzheimer Disease measured with dynamic PET. J Nucl Med. 2017; 58: 1471-1476.
  63. Okamura N, Yanai K. Applications of tau PET imaging. Nat Rev Neurol. 2017; 13: 197-198.
  64. Furumoto S, Tago T, Harada R, Kudo Y, Okamura N. 18F-Labeled 2-arylquinoline derivatives for tau imaging: chemical, radiochemical, biological and clinical features. Curr Alzheimer Res. 2017; 14: 178-185.
  65. Arakawa Y, Nai Y, Shidahara M, Furumoto S, Seki C, Okamura N, Tashiro M, Kudo Y, Yanai K, Gonda K, Watabe H. Prediction of the clinical standardized uptake value ratio in amyloid PET imaging using a biomathematical modeling approach towards the efficient development of a radioligand. J Nucl Med. 2017; 58: 1285-1292.
  66. Neelamegam R, Yokell DL, Rice PA, Furumoto S, Kudo Y, Okamura N, El Fakhri G. A report of the automated radiosynthesis of the tau PET radiopharmaceutical, [18F]-THK-5351. J Labelled Comp Radiopharm. 2017; 60: 140-146.
  67. Betthauser T, Lao PJ, Murali D, Barnhart TE, Furumoto S, Okamura N, Stone CK, Johnson SC, Christian BT. In vivo comparison of tau radioligands 18F-THK-5351 and 18F-THK-5317. J Nucl Med. 2017; 58: 996-1002.
  68. Ishiki A, Harada R, Okamura N, Tomita N, Rowe CC, Villemagne VL, Yanai K, Kudo Y, Arai H, Furumoto S, Tashiro M, Furukawa K. Tau imaging with [18F]THK-5351 in progressive supranuclear palsy. Eur J Neurol. 2017; 24: 130-136.
  69. Miura Y, Yoshikawa T, Naganuma F, Nakamura T, Iida T, Kárpáti A, Matsuzawa T, Mogi A, Harada R, Yanai K. Characterization of murine polyspecific monoamine transporters. FEBS Open Bio. 2017; 7: 237-248.
  70. Stepanov V, Svedberg M, Jia Z, Krasikova R, Lemoine L, Okamura N, Furumoto S, Mitsios N, Mulder J, Långström B, Nordberg A, Halldin C. Development of [11C]/[3H]THK-5351 – A potential novel carbon-11 tau imaging PET radioligand. Nucl Med Biol. 2016; 46: 50-53.
  71. Kikuchi A, Okamura N, Hasegawa T, Harada R, Watanuki S, Funaki Y, Hiraoka K, Baba T, Sugeno N, Oshima R, Yoshida S, Kobayashi J, Ezura M, Kobayashi M, Tano O, Mugikura S, Iwata R, Ishiki A, Furukawa K, Arai H, Furumoto S, Tashiro M, Yanai K, Kudo Y, Takeda A, Aoki M. In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET. Neurology. 2016; 87: 2309-2316.
  72. Schönecker S, Brendel M, Huber M, Vollmar C, Huppertz HJ, Teipel S, Okamura N, Levin J, Rominger A, Danek A. Applied multimodal diagnostics in a case of presenile dementia. BMC Neurol. 2016; 16: 131.
  73. Villemagne VL, Okamura N, Rowe CC. Untangling tau imaging. Alzheimers Dement (Amst). 2016; 4: 39-42.
  74. Harada R, Furumoto S, Tago T, Furukawa K, Ishiki A, Tomita N, Iwata R, Tashiro M, Arai H, Yanai K, Kudo Y, Okamura N. Characterization of the radiolabeled metabolite of tau PET tracer 18F-THK5351. Eur J Nucl Med Mol Imaging. 2016; 43: 2211-2218.
  75. Lockhart SN, Baker SL, Okamura N, Furukawa K, Ishiki A, Furumoto S, Tashiro M, Yanai K, Arai H, Kudo Y, Harada R, Tomita N, Hiraoka K, Watanuki S, Jagust WJ. Dynamic PET measures of tau accumulation in cognitively normal older adults and Alzheimer’s disease patients measured using [18F]THK-5351. PLoS One. 2016; 11: e0158460.
  76. Brendel M, Jaworska A, Probst F, Overhoff F, Korzhova V, Lindner S, Carlsen J, Bartenstein P, Harada R, Kudo Y, Haass C, van Leuven F, Okamura N, Herms J, Rominger Small-animal PET imaging of tau pathology with 18F-THK5117 in 2 transgenic mouse models. J Nucl Med. 2016; 57:792-798.
  77. Okamura N, Harada R, Furukawa K, Furumoto S, Tago T, Yanai K, Arai H, Kudo Y. Advances in the development of tau PET radiotracers and their clinical applications. Ageing Res Rev. 2016; 30:107-113.
  78. Furukawa K, Ishiki A, Tomita N, Onaka Y, Saito H, Nakamichi T, Hara K, Kusano Y, Ebara M, Arata Y, Sakota M, Miyazawa I, Totsune T, Okinaga S, Okamura N, Kudo Y, Arai H. Introduction and overview of the special issue “Brain imaging and aging”: The new era of neuroimaging in aging research. Ageing Res Rev. 2016; 30:1-3.
  79. Harada R, Furumoto S, Yoshikawa T, Ishikawa Y, Shibuya K, Okamura N, Ishiwata K, Iwata R, Yanai K. Synthesis and characterization of 18F-interleukin-8 using a cell-free translation system and 18F-fluoro-L-proline. J Nucl Med. 2016; 57: 634-639.
  80. Harada R, Okamura N, Furumoto S, Tago T, Yanai K, Arai H, Kudo Y. Characteristics of Tau and Its Ligands in PET Imaging. Biomolecules. 2016; 6: 7
  81. Tago T, Furumoto S, Okamura N, Harada R, Adachi H, Ishikawa Y, Yanai K, Iwata R, Kudo Y. Structure-Activity Relationship of 2-Arylquinolines as PET Imaging Tracers for Tau Pathology in Alzheimer’s Disease. J Nucl Med. 2016; 57: 608-14.
  82. Harada R, Okamura N, Furumoto S, Furukawa K, Ishiki A, Tomita N, Tago T, Hiraoka K, Watanuki S, Shidahara M, Miyake M, Ishikawa Y, Matsuda R, Inami A, Yoshikawa T, Funaki Y, Iwata R, Tashiro M, Yanai K, Arai H, Kudo Y. 18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer’s Disease. J Nucl Med. 2016; 57: 208-214.

論文(和文)

  1. 岡村信行,原田龍一.[18F]SMBT-1を用いた反応性アストロサイトのPETイメージング.Dementia Japan 35(3): 339-345, 2021.
  2. 中村正帆,吉川雄朗,柳田俊彦,岡村信行,谷内一彦.オンライン薬理学ロールプレイの実践と課題.日本薬理学雑誌 156(6): 338-344, 2021.
  3. 吉川雄朗,岡村信行.特集:With/after コロナ時代の新たな薬理学教育I:遠隔教育の実践と課題.序文.日本薬理学雑誌 156(6): 323, 2021.
  4. 岡村信行,石木愛子,原田龍一.タウイメージング:最近の進歩と今後の展望.脳神経内科 95(4): 458-464, 2021.
  5. 長沼史登中村正帆岡村信行.視床下部外部ニューロテンシン神経細胞が持つ強力な覚醒作用.Medical Science Digest 47(8): 36-37, 2021.
  6. 岡村信行中村正帆.認知症におけるPETイメージングの現状と展望.Medical Practice 38(8): 1221-1225, 2021.
  7. 原田龍一,岡村信行.タウPETリガンド開発の道程.臨床放射線 66: 317-325, 2021.
  8. 岡村信行.新設の医学部に着任して.日本薬理学雑誌 156(3): 125-126, 2021.
  9. 原田龍一,岡村信行.アストログリオーシスのPETイメージング.Isotope News 772: 10-12, 2020.
  10. 原田龍一,江面道典,工藤幸司,岡村信行.α-シヌクレインのPETイメージング.脳神経内科 91(1): 54-61, 2019.
  11. 古本祥三,原田龍一,Rowe CC,Villemagne VL,岡村信行.【FDG-PETの最近の進歩とこれからの展開】beyond FDG Alzheimer病の神経病理変化を標的とする分子イメージング薬剤の現状と展望.臨床画像 35(8): 933-942, 2019.
  12. 岡村信行中村正帆長沼史登.βアミロイド機能画像.Clinical Neuroscience,37(1):65-67, 2019.
  13. 小林良太,川勝忍,林博史,岡村信行,大谷浩一.若年発症と高齢発症の初期意味障害型進行性失語の神経心理学的・神経放射線学的所見:―1年間の経過比較―.神経心理学 35(4): 238-248, 2019
  14. 原田龍一,岡村信行,古本祥三,谷内一彦.PETを用いた脳タンパク質の可視化.細胞 50(6): 5-8, 2018.
  15. 岡村信行,原田龍一,江面道典,工藤幸司.THK5351-PETから見えてきた分子イメージングの新しい方向性.Dementia Japan 32(4): 538-545, 2018
  16. 吉川雄朗,中村正帆,谷内一彦.新規遺伝子ノックアウトマウスを用いた脳内ヒスタミンクリアランス系の解明.日本薬理学雑誌 152(1): 16-20, 2018
  17. 岡村信行,原田龍一,石木愛子,谷内一彦,荒井啓行,工藤幸司.タウイメージングの現状と将来展望.Dementia Japan 32(2): 196-203, 2018
  18. 岡村信行,石木愛子.認知症の画像診断.JOHNS 34(3): 297-301, 2018
  19. 岡村信行,原田龍一,古本祥三,中村正帆,谷内一彦,工藤幸司.アルツハイマー病理を標的とした分子イメージングプローブの開発.日本薬理学雑誌 150: 172-176, 2017
  20. 岡村信行,原田龍一,長沼史登中村正帆,谷内一彦.認知症治療薬開発のための画像バイオマーカーの臨床評価.臨床薬理の進歩2017, 10-16, 2017
  21. 岡村信行長沼史登中村正帆.薬理からみた自動車運転の諸問題.Modern Physician 37(2): 147-148, 2017
  22. 岡村信行,古川勝敏.タウイメージングの現状と将来展望.臨床放射線 61(12): 1635-1640, 2016
  23. 原田龍一,岡村信行18F-THK5351 PETによるタウイメージング.JSMI Report 10(1): 12-14, 2016
  24. 古川勝敏,石木愛子,冨田尚希,岡村信行,工藤幸司,荒井啓行.認知症診断における分子イメージング.Dementia Japan 30(3), 310-316, 2016
  25. 原田龍一,岡村信行,工藤幸司.βシートリガンドでみる脳内蓄積タンパク質.Dementia Japan 30(2): 271-279, 2016
  26. 岡村信行,石木愛子,古川勝敏.認知症鑑別診断へのタウイメージングの応用.老年精神医学雑誌 27(9): 957-962, 2016
  27. 岡村信行,原田龍一.タウPETによるアルツハイマー病の評価.医学のあゆみ 257(5): 489-493, 2016
  28. 岡村信行.アルツハイマー病の最新診断法.Isotope News 747: 28-29, 2016
  29. 岡村信行.タウイメージングプローブの開発と臨床応用.山形ニューロサイエンス・医工学研究会会誌 16: 1-4, 2016
  30. 岡村信行.病的タンパク質の可視化から見た認知症.Bio Clinica 31(4):28-32, 2016
  31. 工藤幸司,古本祥三,原田龍一,岡村信行.タウイメージング.日本臨床 74(3): 404-409, 2016
  32. 荒井啓行,古川勝敏,冨田尚希,石木愛子,岡村信行,工藤幸司.アルツハイマー病新薬開発の動向.日本臨床 74(3): 411-416, 2016
  33. 原田龍一,岡村信行,古本祥三,工藤幸司,谷内一彦.タウイメージング:18F-THK5351. 最新医学 71: 595-600, 2016

%d人のブロガーが「いいね」をつけました。